Literature DB >> 16133999

Xanthii fructus inhibits inflammatory responses in LPS-stimulated mouse peritoneal macrophages.

Hyo-Jin An1, Hyun-Ja Jeong, Eun-Hee Lee, Yun-Kyung Kim, Woo-Jun Hwang, Su-Jin Yoo, Seung-Heon Hong, Hyung-Min Kim.   

Abstract

Xanthii Fructus (XF) is an herb widely used in medicine for the treatment of a variety of inflammatory pathologies. In this study, using mouse peritoneal macrophages, we have examined whether XF affects nitric oxide (NO), tumor necrosis factor (TNF)-alpha, and interleukin (IL)-12p40 production induced by interferon (IFN)-gamma and lipopolysaccharide (LPS). XF inhibits IFN-gamma and LPS-induced NO production in a dose dependent manner. The decrease in NO synthesis was reflected as a decreased amount of inducible NO synthase protein. Furthermore, we also found that XF inhibits pro-inflammatory cytokine TNF-alpha production. However, treatment of XF in peritoneal macrophages had no effect on IL-12p40 production. These findings suggest that XF may be used in controlling macrophages-mediated inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16133999     DOI: 10.1007/s10753-004-6049-9

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  24 in total

1.  Caffeic acid as active principle from the fruit of Xanthium strumarium to lower plasma glucose in diabetic rats.

Authors:  F L Hsu; Y C Chen; J T Cheng
Journal:  Planta Med       Date:  2000-04       Impact factor: 3.352

2.  Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock.

Authors:  A Petros; D Bennett; P Vallance
Journal:  Lancet       Date:  1991 Dec 21-28       Impact factor: 79.321

Review 3.  Cytokines and autoimmunity.

Authors:  John J O'Shea; Averil Ma; Peter Lipsky
Journal:  Nat Rev Immunol       Date:  2002-01       Impact factor: 53.106

4.  Role of transforming growth factor-beta1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis.

Authors:  M Koyanagi; K Egashira; M Kubo-Inoue; M Usui; S Kitamoto; H Tomita; H Shimokawa; A Takeshita
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

Review 5.  The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1.

Authors:  R Sharma; A J Coats; S D Anker
Journal:  Int J Cardiol       Date:  2000-01-15       Impact factor: 4.164

6.  Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide.

Authors:  L Connelly; M Palacios-Callender; C Ameixa; S Moncada; A J Hobbs
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

7.  Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Authors:  Jennifer D Gorman; Kenneth E Sack; John C Davis
Journal:  N Engl J Med       Date:  2002-05-02       Impact factor: 91.245

8.  The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors.

Authors:  I C Kettelhut; W Fiers; A L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

9.  Inhibitory effects of Xanthii fructus extract on mast cell-mediated allergic reaction in murine model.

Authors:  Seung-Heon Hong; Hyun-Ja Jeong; Hyung-Min Kim
Journal:  J Ethnopharmacol       Date:  2003-10       Impact factor: 4.360

10.  Pertussis toxin-sensitive factor differentially regulates lipopolysaccharide-induced tumor necrosis factor-alpha and nitric oxide production in mouse peritoneal macrophages.

Authors:  X Zhang; D C Morrison
Journal:  J Immunol       Date:  1993-02-01       Impact factor: 5.422

View more
  5 in total

1.  Safety and Efficacy of Medicinal Plants Used to Manufacture Herbal Products with Regulatory Approval in Uganda: A Cross-Sectional Study.

Authors:  Bruhan Kaggwa; Henry Kyeyune; Edson Ireeta Munanura; Godwin Anywar; Stephen Lutoti; Jacqueline Aber; Lynn K Bagoloire; Anke Weisheit; Casim Umba Tolo; Pakoyo Fadhiru Kamba; Patrick Engeu Ogwang
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-13       Impact factor: 2.650

2.  Prediction of the Active Components and Possible Targets of Xanthii Fructus Based on Network Pharmacology for Use in Chronic Rhinosinusitis.

Authors:  Shun Ding; Tingting Duan; Zhengyang Xu; Dongqin Qiu; Jingren Yan; Zhonglin Mu
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-03       Impact factor: 2.629

Review 3.  Recent Progress in Traditional Chinese Medicines and Their Mechanism in the Treatment of Allergic Rhinitis.

Authors:  Dehong Mao; Zhongmei He; Linglong Li; Yuting Lei; Maodi Xiao; Huimin Zhang; Feng Zhang
Journal:  J Healthc Eng       Date:  2022-04-11       Impact factor: 3.822

4.  Xanthii Fructus inhibits allergic response in the ovalbumin-sensitized mouse allergic rhinitis model.

Authors:  Nam-Gil Gwak; Eun-Young Kim; Bina Lee; Jae-Hyun Kim; Yong-Seok Im; Ka-Yeon Lee; Chang Jun-Kum; Ho-Seok Kim; Hyun-Joo Cho; Hyuk-Sang Jung; Youngjoo Sohn
Journal:  Pharmacogn Mag       Date:  2015-10       Impact factor: 1.085

Review 5.  Complementary and integrative treatments: rhinosinusitis.

Authors:  Malcolm B Taw; Chau T Nguyen; Marilene B Wang
Journal:  Otolaryngol Clin North Am       Date:  2013-04-28       Impact factor: 3.346

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.